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A B S T R A C T
Majority of bioequivalence studies are conducted in healthy volunteers. It has been argued that bioequivalence
may not necessarily hold true in relevant patient populations due to a variety of reasons which aﬀect one
formulation more than the other for instance in achlorhydric patients where elevated gastric pH may lead to
diﬀerential eﬀects on formulations which are pH-sensitive with respect to release or dissolution. We therefore
examined achlorhydria-related disparity in bioequivalence of levothyroxine and nifedipine formulations using
virtual bioequivalence within a physiologically-based pharmacokinetic (PBPK) modelling framework. The in
vitro dissolution proﬁles at neutral pH were incorporated into PBPK models to mimic the achlorhydria with in
vitro–in vivo relationship established using bio-relevant pH media. The PBPK models successfully reproduced the
outcome of the bioequivalence studies in healthy volunteers under the normal conditions as well as under proton
pump inhibitor-induced achlorhydria. The geometric mean test/reference ratios for Cmax and AUC between
levothyroxine tablet and capsule in patients receiving proton pump inhibitor were 1.21 (90%CI, 1.13–1.29) and
1.09 (90%CI, 1.02–1.17), respectively. Extension of the virtual bioequivalence study to Japanese elderly, who
show high incidence of achlorhydria, indicated bio-inequivalence which Cmax and AUC ratios between nifedipine
control-released reference and test formulations were 3.08 (90%CI, 2.81–3.38) and 1.57 (90%CI, 1.43–1.74),
respectively. Virtual bioequivalence studies through the PBPK models can highlight the need for conduct of
speciﬁc studies in elderly Japanese populations where there are discrepancies in pH-sensitivity of dissolution
between the test and reference formulations.
1. Introduction
A generic pharmaceutical product is marketed if it is therapeutically
equivalent to the corresponding reference product containing the same
active pharmaceutical ingredient (Davit et al., 2013). Therapeutic
equivalence is assumed if the concentration-time proﬁles are similar.
The same criteria is applied during the development of any propriety
drug product when for variety of reasons the formulation is changed
between early phase clinical studies and later studies prior to getting
the drug into market. The pharmaceutical companies must demonstrate
that the rate and extent of absorption from the new formulation is not
signiﬁcantly diﬀerent from that of the reference formulation. Clinical
studies to establish bioequivalence between two formulations are gen-
erally conducted in young healthy volunteers. The debate over the
conduct of bioequivalence studies in patients as opposed to healthy
volunteers is not a new one (Klintmalm, 2011; Morihara et al., 2001).
However, the possibility to conduct “virtual bioequivalence” using in
silico modelling of the target population is a new concept materialized
with the advent of mechanistic models of oral drug absorption which
combines in vitro information with the physiologically-based pharma-
cokinetic (PBPK) models to postulate in vivo consequences of any dif-
ferences between formulations not only in healthy volunteers but in
variety of other populations who are not typically assessed as part of the
bioequivalence studies (Cristofoletti et al., 2017).
In the current study we have used achlorhydria as an example of
attributes for gastro-intestinal tract that might have diﬀerent incidence
in the target population compared to the healthy volunteer populations
which may cause disparities in the conclusions drawn regarding the
bioequivalence in the two populations. Achlorhydria is deﬁned as a
state of the absence of hydrochloric acid in gastric juices. The pre-
valence of achlorhydria increases with age, and> 70% of Japanese
elderly develop gastric hypoacidity (Morihara et al., 2001). Elevated
gastric pH in achlorhydric elderly may aﬀect bioequivalence between
drug formulations where pH-sensitivity for in vitro dissolution diﬀers.
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Administration of proton pump inhibitors induces gastric hypoacidity
and also has the possibility to produce unacceptable results of bioe-
quivalence between such drug formulations (Seng et al., 2015).
Several generic formulations of drugs such as levothyroxine and
nifedipine show diﬀerent pH-sensitivity of in vitro dissolution to the
corresponding reference formulation (Garbacz et al., 2009; Pabla et al.,
2009; Schug et al., 2002a, 2002b; Wonnemann et al., 2008). Le-
vothyroxine, L-form of thyroid hormone thyroxine used for the treat-
ment of hypothyroidism, is orally administered as tablets or a soft ge-
latin capsule where pH-sensitivity for in vitro dissolution diﬀers
between commercial products. Levothyroxine dissolves slowly from
tablet at mild acidic and neutral pH compared to strong acidity,
whereas soft gelatin capsule containing levothyroxine dissolved in
glycerin shows a consistent dissolution proﬁle without pH-dependency
(Pabla et al., 2009). Once-daily tablet formulations of nifedipine, a
calcium channel blocker used for the treatment of hypertension and
angina, are marketed as control-released (CR) formulations where the
release system diﬀers such as oral osmotic push-pull system (OROS) and
hydrophilic matrix tablets (Garbacz et al., 2009). An OROS tablet of
nifedipine CR provides pH-independent dissolution proﬁles, while the
corresponding hydrophilic matrix tablet has obvious pH-dependency of
in vitro dissolution (Garbacz et al., 2009). Diﬀerent pH-sensitivity of in
vitro dissolution between these formulations raises issues concerning
the possibility that bioequivalence cannot be necessarily assumed the
same in healthy volunteer and achlorhydric patients population. The
aim of study is to examine achlorhydria-related disparity in bioequi-
valence of levothyroxine and nifedipine CR formulations using virtual
bioequivalence within PBPK modelling framework including in vitro–in
vivo correlation (IVIVC) modelling.
2. Materials and methods
A workﬂow for virtual bioequivalence studies using the PBPK
models that were applied to postulate in vivo consequences of any dif-
ferences between formulations is outlined in Fig. 1.
2.1. Formulations
The levothyroxine sodium reference tablet and test capsule for-
mulations used for virtual bioequivalence studies were Synthroid®
(Abbott Laboratories, IL, USA) and Tirosint® (IBSA Institut Biochimique
SA, Switzerland), respectively. The nifedipine CR reference and test
formulations used for virtual bioequivalence studies were Adalat®
OROS (Bayer AG, Germany) and Nifedipine Coral® (So.Se.PHARM S.r.l.,
Italy), respectively. In vitro dissolution proﬁles of the reference and test
formulations for levothyroxine and nifedipine were obtained from the
literature (Garbacz et al., 2009; Pabla et al., 2009). The dissolutions for
levothyroxine formulations were carried out in dissolution medias
containing 0.05% sodium lauryl sulfate, which were 0.1 N hydrochloric
acid representing pH 1.2 and 0.05 M ammonium acetate buﬀers by
adjusting the pH with acetic acid or ammonium hydroxide to 5.0, 6.0,
or 7.0 (Pabla et al., 2009). The dissolutions for nifedipine CR for-
mulations were carried out in USP simulated gastric ﬂuid without en-
zymes pH 1.2 with 1% SDS, USP acetate buﬀer pH 4.5 with 1% SDS,
and USP buﬀer solution for nifedipine extend release tablets pH 6.8
(Garbacz et al., 2009). These dissolution proﬁles were digitized using
GetData Graph Digitizer version 2.26 (Fig. 2). Plasma levothyroxine
concentration proﬁles with or without intravenous administration of
esomeprazole and plasma nifedipine concentration proﬁles under
fasted and fed state were also obtained from the literature and digitized
(Colucci et al., 2011; Schug et al., 2002b; Seng et al., 2015).
2.2. PBPK model development
PBPK modelling and simulation was employed using the Simcyp®
Simulator (V16.1; Certara, Sheﬃeld, UK). PBPK model was developed
Fig. 1. Applied workﬂow for virtual bioequivalence studies using the physiologically-based pharmacokinetic (PBPK) models to postulate in vivo consequences of any diﬀerences between
formulations. PK, pharmacokinetic; ADAM, Advanced Dissolution, Absorption and Metabolism; IVIVC, in vitro–in vivo correlation; IVIVR, in vitro–in vivo relationship.
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using the Advanced Dissolution, Absorption and Metabolism (ADAM)
model to model drug dissolution and absorption. The ADAM model
within the Simcyp Simulator has already been described in detail
(Darwich et al., 2010; Jamei et al., 2009). The ADAM model provides a
variety of options for the input of dissolution rate information such as
separate dissolution proﬁles for gastric and average small intestine pH
values (for both the fed and fasted states). The dissolution rate was
deﬁned as a Weibull function, as shown in Eq. 1 and 2:
= ∙⎡
⎣⎢
− ⎤
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>−
−
F F t lag% 1 whendiss max
t lag
α(%)
( )β
(1)
= ≤F t% 0 when lagdiss (2)
where, %Fdiss is the fraction of drug dose dissolved at time t, Fmax(%) is
the maximum % fraction of drug dose dissolved; lag is the lag time
before dissolution begins; α and β are the Weibull scale and shape
factors for the rate of dissolution, respectively.
The levothyroxine compound ﬁle was developed using the ADAM
module. Physicochemical parameters (molecular weight, log Po:w, acid/
base status and pKa) and fraction unbound in plasma were obtained
from data in the literature and public databases (IBSA Institut
Biochimique SA, 2012; Svanfelt et al., 2011) (Table 1). Blood/plasma
ratio was assumed to be 0.55 from fraction unbound in plasma and
hematocrit reference value of 45% as almost all levothyroxine binds to
plasma proteins (IBSA Institut Biochimique SA, 2012). The simulta-
neous estimation of the eﬀective permeability in humans (Peﬀ,man),
volume of distribution at steady state (Vss), single adjusting compart-
ment (SAC) parameters, and in vivo intravenous clearance (CLiv) was
carried out using the Parameter Estimation module in order to ﬁt a
minimal PBPK model to the observed data (Hays, 1991; Walter-Sack
et al., 2004) (Table 1). The parameter values were estimated from si-
multaneous ﬁtting with observed baseline-adjusted serum concentra-
tion-time proﬁles of levothyroxine in healthy volunteers after the in-
travenous administration (n = 1) and the oral administration of
solution (n = 24) (Hays, 1991; Walter-Sack et al., 2004). The estima-
tion was weighted by the number of individuals in each reported study.
The performance for estimated parameters was veriﬁed by simulation
of 10 trial for 10 subjects (n = 100; Fig. S1). Levothyroxine con-
centration was predicted as baseline-adjusted levothyroxine because it
is diﬃcult to diﬀerentiate between exogenous levothyroxine and se-
creted endogenous thyroxine.
The pre-validated nifedipine compound ﬁle supplied in the Simcyp
compound library was further developed to use the ADAM module for
absorption modelling (Table 2). The Peﬀ,man of nifedipine was estimated
using in vitro MDCK II permeability data (Polli et al., 2001). The same
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(c) Reference nifedipine CR (d) Test nifedipine CR 
(a) Reference levothyroxine tablet (b) Test levothyroxine capsule 
Fig. 2. In vitro dissolution proﬁles of the reference levothyroxine
tablet (a) and capsule (b), and the reference (c) and test (d) nifedi-
pine CR formulations extracted from the literature (Garbacz et al.,
2009; Pabla et al., 2009).
Table 1
Parameter values used for the levothyroxine simulations.
Parameters Value Reference/Comments
Molecular weight (g/mol) 776.9 PubChem
log P 4.12 PubChem
Compound type Ampholyte −
pKa 2.2, 10.1 (Svanfelt et al., 2011)
Fraction unbound in plasma 0.0004 (IBSA Institut Biochimique
SA, 2012)
Blood/plasma ratio 0.55 Assumed from fraction
unbound in plasma
Absorption
Model ADAM
Fraction of drug unbound in enterocyte 1 Simcyp default
Peﬀ,man (×10−4 cm/s) 4.44 PE
Dissolution proﬁle See Table S1 Assumed by IVIVRs (See
main text)
Distribution
Model Minimal PBPK
Vss (L/kg) 0.084 PE
SAC, Kin (1/h) 0.42 PE
SAC, Kout (1/h) 0.22 PE
Vsac (L/kg) 0.000015 PE
Elimination
CLiv (L/h) 0.13 PE
PE, parameter estimation using simultaneous ﬁtting with observed data from the in-
travenous administration (n = 1) and the oral administration of solution (n = 24);
ADAMmodel, Advanced Dissolution, Absorption and Metabolism model; IVIVR, in vitro-in
vivo relationship: Minimal PBPK model, Minimal Physiologically-based Pharmacokinetic
model; SAC, single adjusting compartment.
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Peﬀ,man value was assumed throughout the seven small intestine seg-
ments from duodenum to ileum according to the default approach in
the Simcyp Simulator. The Peﬀ,man value in colon was optimized using
sensitivity analysis, because absorption of nifedipine in colon should be
considered for CR formulation though the absorption was less rapid
from the colon than from the upper part of the gut (Bode et al., 1996).
2.3. IVIVC modelling of dissolution proﬁles
The establishment of IVIVCs was performed using two-stage ap-
proach of IVIVC module within the Simcyp Simulator (Mistry et al.,
2016). The current version of IVIVC module is available for adult hu-
mans only and uses only fasted state parameters. In the ﬁrst step, the in
vivo dissolution proﬁles were deconvolved from the observed plasma
concentration proﬁles of the reference and test formulations. The de-
convolved in vivo dissolution proﬁles were described using a Weibull
function. In the second step, the deconvolved in vivo dissolution proﬁles
from the ﬁrst step were compared to the in vitro dissolution proﬁles in
various pH buﬀers. The IVIVCs between the deconvolved in vivo dis-
solution proﬁle and the in vitro dissolution proﬁle were established in
the condition with the slope of the regression line most closely aligned
with a value of 1.0. If the slope of the regression line closely aligns with
the identity line, the IVIVC provides higher conﬁdence. If the IVIVC was
not established well in above condition, in vitro–in vivo relationship
(IVIVR) was explored by comparing time-dependent proﬁles between
the in vivo dissolution and the in vitro dissolution in various pH buﬀers.
When the deconvolved in vivo dissolution is considerably slower than in
vitro dissolution at appropriate pH, it suggests that the dissolution/re-
lease is not the rate-limiting step of absorption. The IVIVR such as se-
parate dissolution proﬁles for gastric and intestinal pH was established
in the condition with the time-dependent proﬁles suggesting that the in
vivo dissolution at the early time points would be over- or under-esti-
mated by the dissolution at gastric pH. Once the IVIVC/Rs were es-
tablished, the in vitro dissolution proﬁles and the deconvolved in vivo
dissolution proﬁles were used for PBPK modelling (Table S1 and S2). In
vitro dissolution proﬁles were ﬁtted to a Weibull function using Matlab
R2014a (Mathworks, Natick, MA, USA). The Weibull function values
derived from the deconvolved in vivo dissolution proﬁles during
exploring IVIVC/R was used for PBPK modelling when the ﬁtting of the
in vitro dissolution proﬁles resulted in the α value exceeding 100 which
could not be entered within the current version of Simcyp Simulator
(Mistry et al., 2016) (Table S2).
2.4. Trial design
Virtual bioequivalence studies for levothyroxine were simulated
using “healthy volunteers” within Simcyp population library. Trial de-
sign adapted to number of subjects, age, and proportion of females in
the reported clinical study under fasted state (Colucci et al., 2011; Seng
et al., 2015) (Table S3). The reported clinical study for levothyroxine
under intravenous administration of esomeprazole enrolled subjects
having a mean gastric pH≥ 5 during the 2 h after the end of esome-
prazole infusion over 30 min for a maximum dose of 80 mg (Seng et al.,
2015). Levothyroxine formulations were administered to the subjects
under fasting conditions with prior intravenous infusion of esome-
prazole maximum 80 mg over 30 min. The intragastric pH was ap-
proximately 6.5 within the ﬁrst 5 h following the start of the esome-
prazole infusion (Seng et al., 2015). Virtual healthy volunteers under
the intravenous administration of esomeprazole were designed by se-
lecting achlorhydria frequency of 100% in default population. The oral
dose of levothyroxine sodium was set to 0.6 mg with 250 mL water. The
virtual bioequivalence studies were simulated 10 times.
Virtual bioequivalence studies for nifedipine CR were simulated
using “healthy volunteers” and “Japanese” within Simcyp population
library. Trial design for healthy volunteers adapted to number of sub-
jects, age, and proportion of females in the reported clinical study under
fasted/fed state (Schug et al., 2002b) (Table S4). Virtual Japanese
achlorhydric elderly was designed by selecting age range of
60–70 years and achlorhydria frequency of 100% in default Japanese
population. Trial design for Japanese achlorhydric elderly adapted to
number of subjects and proportion of females for healthy volunteers
(Table S4). The oral dose of nifedipine was set to 60 mg with 150 mL
water. When the exposure parameters of nifedipine at steady state were
investigated, the subjects received 60 mg once daily for 7 days. The
virtual bioequivalence studies were simulated 10 times.
Table 2
Parameter values used for the nifedipine simulations.
Parameters Value Reference/Comments
Molecular weight (g/mol) 346.3 Simcyp V16
log P 2.69 Simcyp V16
Compound type Monoprotic base Simcyp V16
pKa 2.82 Simcyp V16
Blood/plasma ratio 0.685 Simcyp V16
Fraction unbound in plasma 0.039 Simcyp V16
Absorption
Model ADAM
Fraction of drug unbound in enterocyte 1 Simcyp V16
MDCK II permeability (×10−6 cm/s) 61 (Polli et al., 2001)
Predicted Peﬀ,man (×10−4 cm/s) 10.5 Predicted using MDCK II Papp-
Peﬀ correlation model in ADAM
Peﬀ,man in colon (×10−4 cm/s) 0.17 Assumed by sensitivity analysis
Dissolution proﬁle See Table S2 Assumed by IVIVCs (See main
text)
Distribution
Model Minimal PBPK
Vss (L/kg) 0.57 Simcyp V16
Elimination
rCYP3A4 Vmax (pmol/min/pmol) 22 Simcyp V16
rCYP3A4 Km (μM) 10.95 Simcyp V16
rCYP3A5 Vmax (pmol/min/pmol) 3.5 Simcyp V16
rCYP3A5 Km (μM) 31.9 Simcyp V16
Renal clearance (L/h) Negligible Simcyp V16
ADAM model, Advanced Dissolution, Absorption and Metabolism model; IVIVC, in vitro-in vivo correlation: Minimal PBPK model, Minimal
Physiologically-based Pharmacokinetic model.
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2.5. Data analysis
Predicted Cmax (maximum serum concentration), Tmax (time to
achieve Cmax), and AUC0 − t (area under the concentration curve from
administration to 24 or 48 h) were compared to the observed values.
Two formulations were deemed bioequivalent if the 90% conﬁdence
intervals (CI) of the geometric mean test/reference for Cmax and AUC
ratios fall within the bioequivalence limits of 80–125% (Davit et al.,
2009). If the geometric mean test/reference for Cmax and AUC ratios has
the potential to be inﬂuenced by diﬀerent gastric dissolution, it was
calculated by combining the simulated results derived from diﬀerent in
vitro dissolution proﬁles. Gastric pH after the intravenous administra-
tion of esomeprazole was generated randomly using R statistical soft-
ware (version 3.3.2). The random generation was performed using the
truncated normal distribution with reported mean and standard de-
viation (6.4 ± 0.9), and truncated on the interval (5.0–7.4) (Seng
et al., 2015). The in vitro dissolution proﬁles at pH 5.0, 6.0, and 7.0 as
gastric pH after the intravenous administration of esomeprazole were
assigned to simulated subjects according to the truncated normal dis-
tribution.
3. Results
3.1. Virtual bioequivalence studies between levothyroxine tablet and capsule
The deconvolved in vivo dissolution proﬁles for the reference tablet
and the test capsule of levothyroxine were compared to the in vitro
dissolution proﬁles in buﬀers of pH 1.2 and 7.0 (Fig. 3a–d). In vivo
dissolution at the early time points for the reference levothyroxine ta-
blet was under-estimated by in vitro dissolution at pH 7.0 (Fig. 3b). The
comparison of time-dependent proﬁles between the in vivo and in vitro
dissolution showed that the in vivo dissolution for the reference le-
vothyroxine tablet was faster than in vitro dissolution at pH 7.0 but was
slower than in vitro dissolution at pH 1.2, suggesting the IVIVR con-
tributing to the in vitro dissolution proﬁles at pH 1.2 and 7.0 as gastric
and intestinal dissolution proﬁles, respectively (Fig. 3e). In vivo dis-
solution for the test capsule did not correspond to in vitro dissolution
proﬁles at pH 1.2 and pH 7.0 (Fig. 3c and d). The slower proﬁles of the
in vivo dissolution than in vitro dissolution for the test capsule showed
that release of dissolved levothyroxine is not rate-limiting step of ab-
sorption, suggesting that the in vitro dissolution proﬁle related to in vivo
(a) Reference levothyroxine tablet, pH 1.2 (b) Reference levothyroxine tablet, pH 7.0 
(c) Test levothyroxine capsule, pH 1.2 (d) Test levothyroxine capsule, pH 7.0 
(e) Reference levothyroxine tablet (f) Test levothyroxine capsule 
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Fig. 3. In vitro-in vivo correlation between in vitro dissolution
at pH 1.2 or 7.0, and deconvolved in vivo dissolution for
dissolution proﬁles of the reference tablet (a and b) and test
capsule (c and d). Time-dependent proﬁles of in vitro dis-
solution at pH 1.2 and 7.0, and deconvolved in vivo dissolu-
tion for the reference tablet (e) and test capsule (f).
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release proﬁle for capsule formulation (Fig. 3f).
The predicted baseline-adjusted plasma levothyroxine proﬁles in
healthy volunteers were successfully recovered for the reference and
test formulations of levothyroxine using a PBPK model with separate in
vitro dissolution proﬁles for stomach and intestine (pH 1.2 and 7.0,
respectively; Table S1), producing results consistent with reported
clinical data (Colucci et al., 2011) (Fig. 4a and b). The predicted Cmax,
Tmax, and AUC were within 2-fold of the observed values for the re-
ference and test formulation in healthy volunteers under fasted state
(Table S5). The geometric mean test/reference ratios for Cmax and AUC
were 1.04 (90%CI, 0.99–1.10) and 0.97 (90%CI, 0.93–1.02) in healthy
volunteers, respectively (Fig. 5 and Table S5). Subsequently, the model
was applied to virtual achlorhydric healthy volunteer population where
gastric pH mimicked that observed following intravenous administra-
tion of esomeprazole. Observed pharmacokinetic proﬁles of baseline-
adjusted plasma levothyroxine in healthy volunteers after the in-
travenous administration of esomeprazole were shown in Fig. 4c.
Pharmacokinetic proﬁles of baseline-adjusted plasma levothyroxine in
virtual achlorhydric healthy volunteers were simulated using the in
vitro dissolution proﬁles at gastric pH 5.0, 6.0, or 7.0 and intestinal
pH 7.0 (Fig. 4d–f). The geometric mean test/reference ratios for Cmax
and AUC diﬀered among gastric pH 5.0, 6.0, and 7.0: the diﬀerence in
exposure between the reference and test formulations was more
pronounced in simulation using the in vitro dissolution proﬁles at gas-
tric pH 5.0 (Fig. 5 and Table S5). The simulated results derived from
diﬀerent in vitro dissolution proﬁles were combined according to dis-
tribution derived from the reported gastric pH under the intravenous
administration of esomeprazole (Fig. S2). The combined geometric
mean test/reference ratios for Cmax and AUC were 1.21 (90%CI,
1.13–1.29) and 1.09 (90%CI, 1.02–1.17), respectively (Fig. 5 and Table
S5).
3.2. Virtual bioequivalence studies for nifedipine CR
The IVIVC produced a good correlation between in vitro and in vivo
dissolution for the reference formulation without pH-dependency
(Fig. 6a). In vivo dissolution for the test formulation under fasted and
fed state corresponded to in vitro dissolution at pH 1.2 and pH 4.5, re-
spectively (Fig. 6b, Fig. 6c).
The predicted plasma nifedipine proﬁles in healthy volunteers
under fasted state were successfully recovered for the reference and test
formulations of nifedipine CR using a PBPK model with deconvolved in
vivo dissolution proﬁles, producing results consistent with reported
clinical data (Schug et al., 2002b) (Fig. 7a and b). The predicted Cmax,
Tmax, and AUC were within 2-fold of the observed values for the re-
ference and test formulation in healthy volunteers under fasted state
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Fig. 4. Simulated and observed plasma levothyroxine con-
centration proﬁles for the reference tablet (a) and test capsule
(b) of levothyroxine in healthy volunteers. Observed plasma
levothyroxine concentration proﬁles for the reference and test
formulations in healthy volunteers after the intravenous ad-
ministration of esomeprazole (c) (Seng et al., 2015). Simu-
lated plasma levothyroxine concentration proﬁles for the re-
ference and test formulations in virtual healthy volunteers
using gastric pH 5.0 (d), pH 6.0 (e), and pH 7.0 (f). The
plasma levothyroxine concentrations were baseline-adjusted.
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(Table S6). The geometric mean test/reference ratios for Cmax, AUC0–24,
and AUC0–48 were 0.98 (90%CI, 0.89–1.07), 0.92 (90%CI, 0.84–1.01)
and 0.91 (90%CI, 0.83–1.00) in healthy volunteers under fasted state,
respectively (Table S6). The PBPK model also reproduced formulation-
speciﬁc food eﬀects using the in vivo dissolution proﬁle for the reference
formulation and in vitro dissolution at pH 4.5 for the test formulation:
the geometric mean test/reference ratios for Cmax, AUC0–24, and
AUC0–48 were 2.02 (90%CI, 1.83–2.23), 1.50 (90%CI, 1.38–1.64) and
1.38 (90%CI, 1.26–1.52), respectively (Fig. 7c, Table S6). Subsequently,
the model was applied to Japanese achlorhydric elderly using the in
vivo dissolution proﬁle for the reference formulation and in vitro dis-
solution at pH 6.8 for the test formulation (Fig. 7d). The predicted
plasma nifedipine concentration proﬁles in Japanese achlorhydric el-
derly subjects showed diﬀerence in exposure between the reference and
test formulations: the geometric mean test/reference ratios for Cmax,
AUC0–24, and AUC0–48 were 3.08 (90%CI, 2.81–3.38), 1.87 (90%CI,
1.71–2.05) and 1.57 (90%CI, 1.43–1.74), respectively (Fig. 8, Table
S6). The exposure parameters under steady state were also examined
after the repeated administration of nifedipine CR once daily for 7 days.
The geometric mean test/reference ratios for Cmax and AUC0–24 after
last dose were 2.82 (90%CI, 2.57–3.08) and 1.55 (90%CI, 1.41–1.70),
respectively (Table S7).
4. Discussion
Appropriate implementation of a virtual bioequivalence study using
a PBPK model may postulate in vivo consequences of any diﬀerences
between formulations in speciﬁc conditions such as achlorhydria.
Incorporation of the ADAM model using diﬀerent dissolution proﬁles
into a PBPK disposition model allowed simulation of pharmacokinetic
proﬁles for drug formulations where pH-sensitivity for in vitro dissolu-
tion diﬀers. Since in vitro dissolution proﬁle does not necessarily cor-
respond to in vivo dissolution proﬁle under the inﬂuences of various
physiological conditions such as gastric emptying, gastrointestinal pH
and ﬂuid dynamics, IVIVC modelling is essential to evaluate and in-
terpret the similarity or diﬀerence between in vitro and in vivo dis-
solution proﬁles (Sjögren et al., 2014). The pH-dependent diﬀerence of
in vitro dissolution proﬁle would be applicable in PBPK modelling when
IVIVC/R was established between in vitro dissolution proﬁle at appro-
priate pH and deconvolved in vivo dissolution proﬁle. The PBPK model
using dissolution proﬁles can be used for virtual bioequivalence study
in speciﬁc patient populations after model veriﬁcation using clinical
data from bioequivalence study in healthy volunteers.
The levothyroxine PBPK model for the virtual bioequivalence study
was developed through the use of physicochemical properties and
pharmacokinetic observations from the administration of intravenous
and oral solution (Fig. S1). The model did not produce IVIVC between
deconvolved in vivo dissolution and in vitro dissolution at both pH 1.2
and 7.0 (Fig. 3). Time-dependent proﬁles between the in vivo and in
vitro dissolution suggested IVIVRs for dissolution from the reference
and test levothyroxine formulations (Fig. 3e and f). The time-dependent
proﬁles of dissolution for the reference tablet showed that the in vivo
dissolution was enhanced at the early time points involved with dis-
solution at stomach. This ﬁnding implied that the higher solubility at
gastric pH resulted in the faster in vivo dissolution than in vitro dis-
solution at intestinal pH. Therefore, an IVIVR using separate in vitro
dissolution proﬁles for gastric and intestinal pH could be incorporated
into the levothyroxine PBPK model. The deconvolved in vivo dissolution
for the test capsule was slower than in vitro dissolution without pH-
sensitivity. This result is supported by characteristics of the test for-
mulation that rapidly releases levothyroxine dissolved in glycerin
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(Fiorini et al., 2016). The in vitro dissolution proﬁle for the test le-
vothyroxine capsule could be used as release proﬁle because release/
dissolution was not the rate-limiting step of absorption. The PBPK
model using the in vitro dissolution proﬁle reproduced the pharmaco-
kinetic proﬁles of levothyroxine for the reference tablet and test capsule
(Fig. 4a and b). Thus, the PBPK model using in vitro dissolution proﬁles
was applicable in virtual bioequivalence study to assess the eﬀect of
proton pump inhibitor on bioequivalence between levothyroxine for-
mulations. The geometric mean test/reference for Cmax and AUC ratios
were calculated by combining the simulated results derived from dif-
ferent in vitro dissolution proﬁles, because the reference levothyroxine
tablet shows diﬀerence in the in vitro dissolution proﬁle among pH 5.0,
6.0, and 7.0. The virtual bioequivalence study successfully reproduced
the geometric mean test/reference for Cmax and AUC ratios from results
observed in the in vivo bioequivalence study (Fig. 5). This virtual
bioequivalence study could raise the possibility that bioequivalence
outcome for levothyroxine formulations was not similar between
healthy volunteers and achlorhydric subjects induced by proton pump
inhibitor. However, simulation in the geometric mean test/reference for
Cmax and AUC ratios showed narrower range of the 90% CIs than those
in observation. This diﬀerence may be caused by the lack of considering
inter-occasion variability in absorption because the administration of
proton pump inhibitor is possible to induce changes in physiological
factors such as gastric emptying rate and small intestinal transit time
(Rasmussen et al., 1999). Development of appropriate population ap-
proaches handling inter-occasion variability is important for ﬁlling gaps
in the accurate prediction of variability in in vivo bioequivalence be-
tween formulations.
The deconvolved in vivo dissolution proﬁles obtained in the ﬁrst step
of IVIVC modelling were employed for the construction of PBPK model
to simulate the plasma nifedipine proﬁles for the reference and test
formulations in healthy volunteers at fasted state (Fig. 7a and b). The
PBPK model using the deconvolved in vivo dissolution proﬁles for the
reference formulation without pH-dependency reproduced the observed
plasma nifedipine proﬁle in healthy volunteers at not only fasted but
also fed state (Fig. 7a–c). In contrast, the test formulation shows the pH-
sensitive in vitro dissolution proﬁles (Fig. 2). The in vivo dissolution
proﬁle deconvolved from pharmacokinetic proﬁle for the test for-
mulation in healthy volunteers under fasted state corresponded to the in
vitro dissolution proﬁle at pH 1.2 but did not to that at pH 6.8 (Fig. 6b).
The result suggested that acidity in gastric ﬂuids where the test for-
mulation ﬁrst contacts could determine the in vivo dissolution proﬁle.
This mechanism is supported by characteristics of test formulation that
the immediate interaction between the polymeric substances contained
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Fig. 7. Simulated and observed plasma nifedipine con-
centration proﬁles for the reference (a) and test (b) nife-
dipine CR formulations in healthy volunteers under fasted
state. Simulated and observed plasma nifedipine con-
centration proﬁles for the reference and test formulations
in healthy volunteers under fed state (c). Simulated plasma
nifedipine concentration proﬁles for the reference and test
formulations in Japanese achlorhydric elderly (d).
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in the test formulation and water/biological ﬂuids causes the hydration
and the distension of the polymeric chains, and control the subsequent
dissolution of nifedipine (So.Se.PHARM S.r.l., 2016). The deconvolved
in vivo dissolution proﬁle for the test formulation under fed state also
corresponded to the in vitro dissolution proﬁle at pH 4.5 (Fig. 6c) where
is close to gastric acidity during the meal, pH 4.9 (Russell et al., 1993),
although the parameters (e.g., gastric empting time and bile salt con-
centration) other than gastric pH also change under fed conditions. The
PBPK model using the in vitro dissolution proﬁle at pH 4.5 reproduced
formulation-speciﬁc food eﬀect for the test formulation (Fig. 7c). These
results based on PBPK and IVIVC modelling suggested that a PBPK
model using in vitro dissolution proﬁle at pH 6.8 for the test formulation
was applicable in virtual bioequivalence study to assess the eﬀect of
achlorhydria on bioequivalence of nifedipine CR formulations. The
virtual bioequivalence study through PBPK and IVIVC modelling re-
vealed that Japanese elderly patients may have altered exposure out-
side the bioequivalence limits (80–125%) due to higher frequency of
achlorhydria (Fig. 8, Table S6 and S7).
The PBPK model for nifedipine CR formulations produced a second
peak in plasma nifedipine proﬁles (Fig. 7a and b) similar to reported
clinical data (Schug et al., 2002b). This second peak may attribute to
absorption of nifedipine in colon, since it was highly sensitive to the
Peﬀ,man value in colon when was optimized using sensitivity analysis.
The predicted plasma nifedipine proﬁle for the reference formulation
was underestimated at 24 h or later after administration compared to
observed proﬁle (Fig. 7a). The previous study has reported that an
ADAM-PBPK model in conjunction with diﬀusion layer model (DLM)
successfully predicted nifedipine pharmacokinetics at 24 h or later for
the reference nifedipine CR formulations despite nifedipine release
mostly completed at 24 h (Patel et al., 2014). The ADAM model with
DLM assuming that the rate limiting step is diﬀusion across a boundary
layer around the solid drug particle of constant thickness handles su-
persaturation and precipitation (Wang and Flanagan, 1999). The DLM
was not used in the modelling work for this study. The assumptions may
improve the prediction of pharmacokinetic proﬁle for the reference
formulation, especially pharmacokinetic proﬁle at 24 h or later. How-
ever, the purpose of this study is to assess virtual bioequivalence using a
PBPK model and in vitro dissolution proﬁle establishing IVIVC.
Bioequivalence guidelines have more similarities than diﬀerences in
the approaches among the regulatory authorities in Australia, Brazil,
Canada, China, Chinese Taipei, the European Medicines Association,
Japan, Mexico, Singapore, South Korea, Switzerland, the USA, and the
World Health Organization (Davit et al., 2013). The recommended
bioequivalence study design is a randomized, single-dose, two-way
crossover in healthy normal subjects. The regulatory authority in Japan
recommends in vivo bioequivalence study in subjects with low gastric
acidity in cases where the test and reference products show a signiﬁcant
diﬀerence in in vitro dissolution at around pH 6.8, or between
pH 3.0–6.8 for basic drugs (MHLW, 2012). The other regulatory au-
thorities have no recommendation in these cases despite the fact that
bioequivalence cannot be necessarily assumed the same in patients and
healthy volunteers population. However, we faces situation where
proton pump inhibitors which induce low gastric acidity are extensively
used around world, and the prevalence of proton pump inhibitors use
increases with age (Hassing et al., 2016; Lazarus et al., 2016; Lødrup
et al., 2014; Nishtala and Soo, 2013; Patterson et al., 2013). Therefore,
the eﬀect of low gastric acidity on bioequivalence outcome should be
investigated if the test and reference products show a signiﬁcant dif-
ference in in vitro dissolution at neutral pH. An in vivo bioequivalence
study in subjects with low gastric acidity could be conducted with
diﬃculties such as recruitment of achlorhydric subjects whose pre-
valence is typically less in healthy volunteers than in Japanese elderly
and temporary induction of achlorhydria by gastric acid reducers in
healthy subjects. Under certain conditions, virtual bioequivalence study
through PBPK framework including IVIVC modelling may be proposed
as an alternative means of in vivo bioequivalence study in subjects with
low gastric acidity.
The present virtual bioequivalence studies for levothyroxine and
nifedipine CR through the PBPK models indicated the possibilities that
bioequivalence was not established between the reference and test
formulations in achlorhydric subjects. However, the disparity in bioe-
quivalence outcome between healthy volunteers and achlorhydric
subjects was less pronounced for levothyroxine formulations as com-
pared to nifedipine CR. This attributes to diﬀerence in pharmaceutical
properties such as release rate (e.g. immediate release and extended
release) and release system (e.g. OROS and hydrophilic matrix). The
formulation-speciﬁc bioequivalence outcome in achlorhydric subjects
would be also inﬂuenced by other drug properties such as low and high
permeability, low and high metabolism, and involvement with pH-
sensitive uptake transporter. The peptide transporter PEPT1 mediates
active absorption of peptidomimetic drugs with proton gradient and
luminal pH providing the driving force, and the PEPT1 substrates ex-
hibit diﬀerent pH-sensitive transport proﬁles (Brodin et al., 2002;
Nozawa et al., 2003; Wenzel et al., 1996). Future virtual bioequivalence
studies for achlorhydric subjects may be interested in drugs of various
pharmaceutical classes and pH-sensitive uptake transporter substrates,
and may oﬀer the possibility to make a kind of classiﬁcation about the
need or not for speciﬁc bioequivalence study.
5. Conclusions
Virtual bioequivalence studies through the PBPK models success-
fully predicted the bioequivalence outcomes for levothyroxine and ni-
fedipine CR formulations in healthy volunteers. However, it suggested
that Japanese elderly and patients receiving proton pump inhibitor may
have altered exposure outside the bioequivalence limits (80–125%) due
to higher frequency of achlorhydria. The reverse could be true if the
formulations behaved diﬀerently in acidic media but similar in basic
environment. Virtual bioequivalence studies through the PBPK models
can highlight the need for conduct of speciﬁc studies in elderly
Japanese populations where there are discrepancies in pH-sensitivity of
dissolution between the test and reference formulations. Further de-
velopment of PBPK modelling, such as considering inter-occasion
variability, may allow providing the accurate prediction of variability
in in vivo bioequivalence between formulations.
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